Pediatric Scrub Typhus Manifesting with Multisystem Inflammatory Syndrome: A New Cause for Confusion or Concern—A Case Series

Parveen Bhardwaj¹,², Mangla Sood³, Rajender Singh³

Abstract

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has discovered a new disease called multisystem inflammatory syndrome in children (MIS-C). In developing nations, pediatricians must be mindful of the similarities between MIS-C and other tropical fevers such as scrub typhus. Not only should such patients be kept on high alert to rule out tropical diseases and receive appropriate treatment; such as steroids or immunomodulatory medications, but this is also concerning because, if rickettsial or bacterial infection is not detected through cultures and serology, steroid, or immunomodulatory treatment alone can be fatal.

Keywords: Child, Multisystem inflammatory syndrome in children, Rickettsia, Scrub typhus, Severe acute respiratory syndrome.

Introduction

Scrub typhus is a febrile infection caused by Orientia tsutsugamushi, a gram-negative coccobacillus, transmitted by the bite of an infected larval trombiculid mite.¹ It has been reported worldwide,² including India³⁴ during the summer and autumn in rural areas. Close differential diagnosis is other endemic febrile illnesses and correlated with compatible clinical signs, symptoms, laboratory findings along with epidemiologic indicators (e.g., recent exposure to locations where chiggers are suspected to be present). A lymphohistiocytic vasculitis with extensive vascular dysfunction and endothelial damage is the histological hallmark of the disease.

Recently, a serious condition multisystem inflammatory syndrome in children (MIS-C) has been diagnosed among patients who tested positive for coronavirus disease-2019 (COVID-19) (by PCR or serology) or showed epidemiologic linkages to COVID-19.⁵,⁶ MIS-C appears to be an excessive immune response related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with symptoms of persistent fever and hyperinflammation, as well as cardiac, gastrointestinal, renal, hematologic, dermatologic, and neurologic problems. We describe the clinical characteristics, laboratory data, and treatment management of pediatric scrub typhus patients manifesting as MIS-C in a northern Indian hospital.

Case Series

Between August and October 2021, children admitted into pediatric intensive care unit (PICU) of a tertiary care teaching hospital in northern India with unexplained fever and symptoms of multisystemic involvement were investigated for COVID NAAT as well as serology, tropical infections scrub, dengue, typhoid, malaria, and blood and urine cultures. The hospital records of all patients who had a positive Scrub IgM ELISA serology and symptoms, signs, and laboratory markers consistent with systemic hyperinflammatory disease were reviewed retrospectively.

Clinical Characteristics, Laboratory Findings, Treatment, and Outcome

Table 1 displays clinical characteristics, laboratory, and treatments of all patients with outcomes. Table 2 displays the echocardiogram (ECHO) findings of all patients. Three of the nine patients were males, with a median age of 11.2 years (range 6.6–15.8 years). Mean weight was 34.1 kg (±15.4), mean height 133.5 cm (±32.3). All the three females who were underweight died. None of the patients tested COVID NAAT positive, while two with positive COVID serology survived.

At the time of admission, erythematous rash without an eschar (ESCHAR) was present in seven (77.8%), gastrointestinal involvement in eight (88.9%), shock in eight (88.9%), altered sensorium in three (33.3%), eight (88.9%) developed acute respiratory distress syndrome (ARDS) within 24 hours of admission, three (33.3%) patients had cardiac involvement, one had ECHO finding suggestive of myocardial dysfunction, and ejection fraction of 40%. None had coronary vessel abnormalities. Laboratory tests revealed anemia in all patients, range of Hb 8–10.7 gm/dL, low total leucocyte count (TLC) in three (33.3%) with lowest value 1200. Lymphopenia was present in five (55.5%) with lowest count 200 and all patients had...
Table 1: Demographic characteristics, laboratory values, treatment, and outcome of patients

| Baseline characters | Name, Sex | 1     | 2     | 3     | 4     | 5     | 6     | 7     | 8     | 9     |
|---------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Age in months       | J, Male   | 23    | 168   | 192   | 156   | 72    | 204   | 34    | 164   | 200   |
| Weight in kg        | P, Male   | 12    | 45    | 45    | 40    | 18    | 50    | 12    | 45    | 40    |
| Height in cm        | S, Female | 80    | 154   | 140   | 135   | 113   | 157   | 90    | 168   | 165   |
| Scrub IgM           | V, Female | Positive | Positive | Positive | Positive | Positive | Positive | Positive | Positive |
| COVID PCR/RAT positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| COVID serology      | R, Male   | Positive | Positive | Positive | Positive | Positive | Positive | Positive | Positive |
| Rash                | M, Female | Present | Present | Absent | Present | Present | Present | Present | Absent |
| Conjunctivitis      | P, Female | Absent | Absent | Absent | Absent | Absent | Absent | Absent | Absent |
| Oral ulcers         | A, Female | Absent | Present | Absent | Absent | Absent | Present | Present | Absent |
| Gastrointestinal involvement | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Shock               | A, Female | Absent | Present | Present | Present | Present | Present | Present | Present |
| Altered sensorium   | Absent | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| Respiratory symptoms | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Cardiac involvement (either Lab/ECHO) | Absent | Present | Absent | Absent | Absent | Absent | Present | Absent | Absent |
| LVEF %              | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Preexisting comorbidities | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Duration of fever/illness in days | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Duration of hospital stay in days | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Laboratory          | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Hemoglobin (gm/dL)  | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Total leukocyte counts (mm$^3$) | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Lymphocyte count (mm$^3$) | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| ANC (mm$^3$)        | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Platelet count (mm$^3$) | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| ESR (mm/hour)       | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| CRP (mg/dL)         | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| Serum ferritin (ng/mL) | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| NT-proBNP (pg/mL)   | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| D-dimer (ng/mL)     | Absent | Present | Present | Present | Present | Present | Present | Present | Present |
| PaO₂/FIO₂ ratio | 400 | 110 | 250 | 124 | 250 | 290 | 135 | 150 |
|-----------------|-----|-----|-----|-----|-----|-----|-----|-----|
| PT/INR/APTT     | 14.7/1/1/30 | 17.8/2.1/45.4 | 14.8/1.12/38.9 | 14.6/1.2/34.6 | 13.7/1.01/37 | 13.7/1.2/40.1 | 25.7/2/62.8 | 30.2/3/71.2 | 24/2.2/68 |
| Urea/Cr         | 10/0.38 | 42/1.02 | 22/0.7 | 20/0.68 | 16/1.0 | 12/0.7 | 7/0.3 | 26/1.1 | 20/0.67 |
| Albumin/ALT/AST | 3.5/23/52 | 1.9/158/120 | 2.2/129/61 | 3/68/54 | 3/47/54 | 2.5/39/72.5 | 2.2/21/44 | 2.3/98/108 | 2/70/70 |

**Treatment**

| Duration of inotropic support in hours, type | 20, noradrenaline | 44, noradrenaline | 62, noradrenaline and adrenaline | 60, noradrenaline and adrenaline | 110, noradrenaline and adrenaline | 48, noradrenaline | 24, noradrenaline | 72, noradrenaline | 120, noradrenaline |
|---------------------------------------------|-------------------|-------------------|-------------------------------|-------------------------------|-------------------------------|-------------------|-------------------|-------------------|-------------------|
| Duration of mechanical ventilation          | Not required      | 6 days            | 5 days                        | Not required                  | 10 days                      | Not required      | 1 day             | 3 days            | 11 days           |
| IV Ig with dose                              | Not given         | Not given         | Not given                    | 1 dose @ 2 g/kg               | 1 dose @ 2 g/kg              | Not given         | 1 dose @ 2 g/kg   | 1 dose @ 2 g/kg   | Not given         |
| Duration of steroids, type, and dose         | 7 days methylprednisolone @30 mg/kg/day for 3 days, tapered over 4 weeks | 7 days methylprednisolone @10 mg/kg/day then shifted to oral prednisolone @2 mg/kg/day | 7 days methylprednisolone @30 mg/kg/day then shifted to oral prednisolone @10 mg/kg/day | 7 days methylprednisolone @10 mg/kg/day then shifted to oral prednisolone @2 mg/kg/day | 7 days methylprednisolone @30 mg/kg/day for 3 days, tapered over 4 weeks | 7 days methylprednisolone @30 mg/kg/day | 3 days, methylprednisolone @30 mg/kg/day | 7 days, methylprednisolone @30 mg/kg/day |
| Duration of antibiotics, name                | Doxycycline × 7 days, Ceftriaxone × 10 days | Doxycycline × 10 days, Ceftriaxone × 10 days | Doxycycline × 7 days, Ceftriaxone × 12 days | Doxycycline × 7 days, Ceftriaxone × 10 days | Doxycycline × 6 days, Linezolid × 15 days | Doxycycline × 6 days | Doxycycline × 6 days | Doxycycline × 6 days | Doxycycline × 6 days |
|                                            |                   |                   |                               |                               |                               |                   |                   |                   |                   |
| Outcome                                     | Discharged alive  | Discharged alive  | Discharged alive              | Discharged alive              | Discharged alive              | Discharged alive  | Death             | Death             | Death             |

ALT/AST, alanine aminotransferase/aspartate aminotransferase; ANC, absolute neutrophil count; CRP, creative protein; Cr, creatinine; ESR, erythrocyte sedimentation rate; IV Ig, Intravenous immune globulin; LVEF, left ventricle ejection fraction; NT-proBNP, N-terminal pro b-type natriuretic peptide; PCR/RAT, polymerase chain reaction/rapid antigen test; PT, prothrombin time and partial thromboplastin time
thrombocytopenia with lowest count 19,000: elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Seven (77.8%) had elevated ferritin and D-dimer value, all except one had PaO2/FiO2 ratio less than 300, and four (44.4%) had coagulopathy. All patients had more than 3 days of fever before admission, (range 4–8 days). Total hospital duration ranges from 3 to 15 days, with a median of 10.6 days.

All patients required inotropic support and remained on noradrenaline infusion, median time 62 hours (range 20–120 hours), two patients required adrenaline infusion in addition. Eight patients required mechanical ventilation for median 4 days (range 1–11 days), four (44.5%) were given 2 g/kg IVIg within 48 hours of admission. Two parents refused for IVIg citing financial reasons. In addition, all patients received high-dose methylprednisolone for 3–7 days and were tapered off subsequently. All patients received antibiotics, including doxycycline in accordance with the ICU protocol. Three (33.3%) patients died. There was no significant correlation with any particular symptom, COVID serology positivity, duration of fever, laboratory values, intravenous immunoglobulin (IVIg) and steroids, choice, and duration of antibiotics with death (p >0.05) (Table 4).

**DISCUSSION**

According to early reports of SARS-CoV-2 patients, the sickness was more common and severe in elderly persons and people with comorbidities compared to children. However, incidences of severe multisystem hyperinflammatory syndrome in children were shortly reported from a number of countries. The World Health Organization (WHO) provided a case definition for MIS-C which include patients under 19 years of age with ≥3 days fever, laboratory evidence of inflammation, and involvement of two or more organ systems (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological), with positive testing for SARS-CoV-2 indicating current or recent infection or COVID-19 exposure; and no other alternative plausible diagnoses. With the ongoing COVID-19 pandemic, clinicians have been on the lookout for MIS-C; and in countries like ours, many tropical infections such as scrub typhus, leptospirosis, malaria, dengue, Kawasaki syndrome, and toxic shock syndrome have been close differential diagnoses in the initial 2–3 days when laboratory investigations for alternative diagnosis are not available.

In Himachal Pradesh, postmonsoon months always see a spike in cases of scrub typhus among adults and children. Few critically sick children presented in shock with multiple organ dysfunction syndrome (MODS) and during the initial 2–3 days satisfied the case definition of MIS-C pending IgM enzyme linked immunoassay (ELISA) report for scrub typhus. We treated these children according to MIS-C protocol, in addition to antibiotics for tropical infections including scrub. Recently, a case report of dengue presenting as
Table 4: Correlation of various variables with mortality among scrub typhus patients presenting as MIS-C

|                         | Alive | Dead | p value |
|-------------------------|-------|------|---------|
| COVID serology −ve      | 4     | 3    | 0.25    |
| COVID serology +ve      | 2     | 0    |         |
| Rash −ve                | 1     | 1    | 0.57    |
| Rash +ve                | 5     | 2    |         |
| GIT symptoms −ve        | 1     | 0    | 0.45    |
| GIT symptoms +ve        | 5     | 3    |         |
| Shock −ve               | 1     | 0    | 0.45    |
| Shock +ve               | 5     | 3    |         |
| Altered sensorium −ve   | 5     | 1    | 0.13    |
| Altered sensorium +ve   | 1     | 2    |         |
| Respiratory symptoms −ve| 1     | 0    | 0.45    |
| Respiratory symptoms +ve| 5     | 3    |         |
| Cardiac involvement −ve | 4     | 3    | 1.0     |
| Cardiac involvement +ve | 2     | 0    |         |

GIT, gastrointestinal symptoms

MIS-C has also been published; therefore, tropical fevers in children should always be its close differential.\(^1\)

However, our case series also has two patients with positive COVID serology, complicating the final diagnosis. The community transmission of COVID infection could explain the positive SARS-CoV-2 antibodies among scrub typhus patients, with many children with asymptomatic infections during peak of COVID pandemic may be showing serological evidence now. This is concerning because, if rickettsia or bacterial infection is not detected through cultures and serology, steroid or immunomodulatory treatment alone can be fatal.\(^5\) We need to be vigilant and rule out tropical infections and administer appropriate treatment, along with steroids or immunomodulatory drugs among such patients. In the previous years too, scrub typhus patients had presented with shock and MODS, but we were not giving steroids and immunomodulatory treatment for associated hyperinflammation, due to concern about worsening of the infection.

In this case series, we had favorable prognosis among scrub typhus patients with hyperinflammation when steroids and IV Ig were combined with doxycycline. We recommend randomized controlled trials to establish definitive role of steroids and immunomodulatory treatment in improving the outcome of scrub typhus children presenting with hyperinflammation.

**References**

1. Sonthayanon P, Chierakul W, Wuthiekanun V, Phimda K, Pukrittayakamee S, Day NP, et al. Association of high Orientia tsutsugamushi DNA loads with disease of greater severity in adults with scrub typhus. J Clin Microbiol 2009;47(2):430–434. DOI: 10.1128/JCM.01927-08.
2. Bonell A, Lubell Y, Newton PN, Crump JA, Paris DH. Estimating the burden of scrub typhus: a systematic review. PLoS Negl Trop Dis 2017;11(9):e0005838. DOI: 10.1371/journal.pntd.0005838.
3. Rathi N, Rathi A. Rickettsial infections: Indian perspective. Indian Pediatr 2010;47(2):157–164. DOI: 10.1007/s13312-010-0024-3.
4. Gupta S, Bansal A, Biswal M, Williams V, Zaman K, Kumar A. Clinical profile and predictors of intensive care unit admission in pediatric scrub typhus: a retrospective observational study from North India. Indian J Crit Care Med 2020;24(6):445–450. DOI: 10.5005/jp-journals-10071-23445.
5. Sood M, Sharma S, Sood I, Sharma K, Kaushik A. Emerging evidence on multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection: a systematic review with meta-analysis. SN Compr Clin Med 2021;3(1):38–47. DOI: 10.1007/s42399-020-00690-6.
6. Shobhavat L, Solomon R, Rao S, Bhagat I, Prabhu S, Prabhu S, et al. Multisystem inflammatory syndrome in children: clinical features and management-intensive care experience from a pediatric public hospital in Western India. Indian J Crit Care Med 2020;24(11):1089–1094. DOI: 10.5005/jp-journals-10071-23658.
7. Burstein R, Henry NJ, Collison ML, Marczak LB, Sligar A, Watson S, et al. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature 2019;574(7778):353–358. DOI: 10.1038/s41586-019-1545-0.
8. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 [Accessed October 15, 2021]. Available from: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.
9. Indian Academy of Pediatrics (IAP) [get latest guidance on COVID-19 [Accessed October 23, 2021]. Available from: https://iapindia.org/get-latest-guidance-on-COVID-19/.
10. Yang J, Luo L, Chen T, Li L, Xu X, Zhang Y, et al. Efficacy and safety of antibiotics for treatment of scrub typhus. JAMA Netw Open 2020;3(8):e2014487. DOI: 10.1001/jamanetworkopen.2020.14487.
11. Samprathi M, Narayanappa S, Sridhar M, Ramachandra P, Vemgal P. Multisystem inflammatory syndrome in children: a mimicker of severe dengue. Indian J Pediatr 2021;88(5):486–487. DOI: 10.1007/s12098-020-03550-2.